| Literature DB >> 33324206 |
Roodabeh Bahramsoltani1,2, Roja Rahimi1,2.
Abstract
A new coronavirus causing severe acute respiratory syndrome (SARS-CoV-2) has emerged and with it, a global investigation of new antiviral treatments and supportive care for organ failure due to this life-threatening viral infection. Traditional Persian Medicine (TPM) is one of the most ancient medical doctrines mostly known with the manuscripts of Avicenna and Rhazes. In this paper, we first introduce a series of medicinal plants that would potentially be beneficial in treating SARS-CoV-2 infection according to TPM textbooks. Then, we review medicinal plants based on the pharmacological studies obtained from electronic databases and discuss their mechanism of action in SARS-CoV-2 infection. There are several medicinal plants in TPM with cardiotonic, kidney tonic, and pulmonary tonic activities, protecting the lung, heart, and kidney, the three main vulnerable organs in SARS-CoV-2 infection. Some medicinal plants can prevent "humor infection", a situation described in TPM which has similar features to SARS-CoV-2 infection. Pharmacological evaluations are in line with the therapeutic activities of several plants mentioned in TPM, mostly through antiviral, cytoprotective, anti-inflammatory, antioxidant, and anti-apoptotic mechanisms. Amongst the primarily-introduced medicinal plants from TPM, rhubarb, licorice, garlic, saffron, galangal, and clove are the most studied plants and represent candidates for clinical studies. The antiviral compounds isolated from these plants provide novel molecular structures to design new semisynthetic antiviral agents. Future clinical studies in healthy volunteers as well as patients suffering from pulmonary infections are necessary to confirm the safety and efficacy of these plants as complementary and integrative interventions in SARS-CoV-2 infection.Entities:
Keywords: Traditional Persian medicine; antioxidant; coronavirus; herbal medicine; phytochemical
Year: 2020 PMID: 33324206 PMCID: PMC7724033 DOI: 10.3389/fphar.2020.571434
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Medicinal plants with possible beneficial effects in treating COVID-19 based on Traditional Persian Medicine.
| Scientific name/common name | Persian names | Part | Preventing the infection of humors | Preventing the excitation of humors | Cardiotonic properties | Pulmonary tonic properties | Kidney tonic properties | Reference |
|---|---|---|---|---|---|---|---|---|
|
| Samgh-e-Arabi | Gum | + | ( | ||||
|
| Soom, Sir | Bulb | + | + | + | ( | ||
|
| Khoulanjān | Rhizome | + | + | ( | |||
|
| Oud-e-Hendi | Wood | + | ( | ||||
|
| Zereshk, ambarbāris (fruit), | Fruit, root | + | + | ( | |||
|
| Nokhod | Seed | + | ( | ||||
|
| Kāsni, Hendabā | Seed, root, leaf | + | + | + | + | ( | |
|
| Morr-e-Macci | oleo-gum resin | + | ( | ||||
|
| Geshniz, Kozboreh | Fruit | + | ( | ||||
|
| Zaferān | Stigma | + | + | + | ( | ||
|
| Safarjal, Beh | Fruit | + | ( | ||||
|
| Ezkher | Leaf | + | + | ( | |||
|
| Lesān-al-sour, gāv zaban | Flower | + | ( | ||||
|
| Hel | Seed | + | ( | ||||
|
| Anjeer, Tin | Fruit | + | ( | ||||
|
| Shātareh | Aerial parts | + | ( | ||||
|
| Gentianā | Root | + | ( | ||||
|
| Shirin bayan, sous | Root | + | ( | ||||
|
| Shaeer, Jo | Seed | + | ( | ||||
|
| Rāsan | Root | + | + | ( | |||
|
| Bālangu | Seed | + | ( | ||||
|
| Ghār, Barg-e-Bou | Leaf, fruit | + | + | ( | |||
|
| Sib, Toffāh | Fruit | + | ( | ||||
|
| Bādranjbouyeh | Leaf | + | ( | ||||
|
| Niloufar | Flower | + | ( | ||||
|
| Ameleh | Fruit | + | + | ( | |||
|
| Mastaki | Oleo-gum-resin | + | ( | ||||
|
| Bārhang | Seed | + | ( | ||||
|
| Reevand | Root | + | ( | ||||
|
| Vard, Gol-e-Mohammadi | Flower | + | + | + | ( | ||
|
| Beedmeshk | Flower | + | + | ( | |||
|
| Sandal | Wood | + | ( | ||||
|
| Gharanfol, Mikhak | Flower bud | + | + | ( | |||
|
| Tamr-e-Hendi | Fruit | + | + | ( | |||
|
| Holbeh, Shanbalileh | Seed | + | ( | ||||
|
| Enab, angour (fresh), | Fruit juice | + | + | ( | |||
|
| Onnab | Fruit | + | ( |
Pharmacological studies on the medicinal plants predicted to be useful in SARS-CoV-2 infection based on traditional Persian medicine.
| General category of therapeutic activity | Scientific name/preparation | Model/Design | Dosage and duration of treatment | Mechanisms | Reference |
|---|---|---|---|---|---|
| Antiviral activity | |||||
|
|
| 10-1000 μM | ↓TNF-α, IL-8, IL-10, LPO, iNOS | ( | |
|
|
| – | ↓Nuclear export of viral ribonucleoprotein complex (IC50 = 12.8 μM), | ( | |
|
|
| 5-20 μM | ↓Nuclear transport of Rev by direct binding of Cys-529 in chromosomal region maintenance-1 | ( | |
|
|
| – | RSV: EC50 = 5-42 μg/ml, SI=0.9->6.1 | ( | |
|
|
|
| ↓Viral messenger RNA & antigens, No effect on virus adsorption or invasion, | ( | |
|
|
| – | ↓Viral replication by crocin & picrocrocin: | ( | |
|
|
| – | Higher anti-HIV effect with alkaline extract (EC50 = 54-167 μg/ml, SI=3-9) | ( | |
|
|
| 25-200 μg/ml | ↓Apoptosis, viral replication, IL-6, MCP-1, CCL5, CXCL10, ROS, | ( | |
|
|
| – | ↓Viral replication (EC50 = 300, 600 mg/l, SI=33, 67), | ( | |
|
|
| – | IC50 (μg/ml): | ( | |
|
|
| – | 18β-glycyrrhetinic acid: | ( | |
|
|
| – | IC50 = 9 μg/ml for aqueous & 10 μg/ml for MeOH extracts. | ( | |
|
|
| – | IC50: | ( | |
|
|
|
|
| ( | |
|
|
| 29.6 μM | ↓Viral replication, maturation, & virulence, | ( | |
|
|
| – | ↓Infectivity (EC50 = 4- >250 μg/ml, SI=5- >100), | ( | |
|
|
| 100 μg/ml | 76% % 90% inhibition by the MeOH & aqueous extracts, | ( | |
|
|
| 5 μg/ml | ↓Virus-induced autophagy & cell death, virus replication, | ( | |
|
|
| 2.5-20 μg/ml | ↓HCV replication, COX-2, NF-κB & MAPK/ERK/JNK signaling, | ( | |
|
|
| 5, 10 μg/ml | ↓Viral replication, viral nucleoprotein & fusion protein, | ( | |
|
|
|
|
| ( | |
| Cardioprotective activity |
| DOX-induced cardiotoxicity in rat | 20 mg/kg/day, p.o., 14 days | ↑CAT, SOD, Gpx, | ( |
|
| I/R-induced cardiotoxicity in mouse | 100 mg/day, i.p., two doses | ↓Cardiomyocyte apoptosis & infarct size, | ( | |
|
|
|
|
| ( | |
|
| Fructose-induced cardiotoxicity in diabetic rat | 250 mg/kg/day, p.o., 8 weeks | ↓NF-κB, ROS, LPO, NO, | ( | |
|
| DOX-induced cardiotoxicity in mouse | 20-80 mg/kg/day, p.o., 28 days | Improvement of cardiac function, | ( | |
|
| ISO-induced cardiotoxicity in rat | 200-800 mg/kg/day, p.o., 28 days | Improvement of hemodynamic function of heart, | ( | |
|
| ISO-induced cardiotoxicity in rat | 20-160 mg/kg/day of extract or 0.025-0.075 of safranal, i.p., 9 days | ↓LDH, CK-MB, LPO, | ( | |
|
|
| 10-40 μM | ↑Viability, thiol content | ( | |
|
| DOX-induced cardiotoxicity in rat | 20, 40 mg/kg/day, i.p., 20 days | Improvement of heart function, ECG, & histopathological damages | ( | |
|
|
| 10 μg/ml | ↑Viability, α-actinine, troponine C & MLC, AKT/P70S6K & ERK1/2 activity, | ( | |
|
|
| 20-200 μg/ml | ↓ROS, DNA damage, mitochondrial dysfunction, | ( | |
|
| I/R-induced cardiotoxicity in rat | 400 mg/kg, p.o., 30 days | ↑SOD, Gpx, CAT, GSH, | ( | |
|
| ISO-induced cardiotoxicity in rat | 10, 20 mg/kg, p.o., 2 days | Modulation of ECG & morphology, | ( | |
|
| I/R-induced cardiotoxicity in rat | 100 mg/kg/day, p.o., 30 days | Upregulation of PI3K/Akt/GSK3β/β-catenin & Bcl-2, | ( | |
|
| I/R-induced cardiotoxicity in rat | 100 & 200 mg/kg/day, p.o., 14 days | ↑Cardiac SOD, CAT, Gpx, | ( | |
|
| ISO-induced cardiotoxicity in rat | 100-500 mg/kg/day, p.o., 30 days | Restoration of hemodynamic parameters & cardiac function, | ( | |
|
| STZ-induced diabetic myocardial dysfunction in rat | 1 ml/kg/day, p.o., 8 weeks | Restoration of hemodynamic parameters, | ( | |
|
| Isolated perfused beating rabbit atria | 10-100 μM | ↑Atrial natriuretic peptide, | ( | |
|
|
|
|
| ( | |
|
| I/R-induced cardiotoxicity in H9c2 murine cardiocyte | 1 μg/ml | ↓Apoptosis, ROS, p-P38, | ( | |
|
| Isolated guinea pig heart un-treated or pretreated with propranolol, methacholine, & diltiazem | 0.1-1 mg% | ↑Heart rate & contractility, | ( | |
|
| ISO-induced cardiotoxicity in rat | 2.5-10 mg/kg/day, p.o., 10 days | ↓CK-MB, Cr, LDH, AST, ALT, LPO, | ( | |
|
|
| 0.01-1 mg/ml, |
| ( | |
|
| ISO+ hypercholesterolemic diet-induced cardiotoxicity in rat | 10% of diet, p.o., 8 weeks | ↓LDH, CK-MB, AST, ALT, | ( | |
|
| STZ-induced cardiotoxicity in diabetic rats | 9 g/kg/day, p.o., 30 days | ↑Activity of cardiac SOD, CAT, GSH, GST, | ( | |
|
| STZ-induced cardiotoxicity in diabetic rats | 10% of the diet weight, 6 weeks | ↓RAS activity, type IV collagen, fibronectin, Bax, 4-hydroxynonenal, iNOS, nitrate/nitrite, | ( | |
|
| ISO-induced cardiotoxicity in rat | 20-80 mg/kg/day, p.o., 20 days | ↓Infarction area, | ( | |
|
| DOX-induced cardiotoxicity in rat | 70 mg/kg, p.o., 10 days | Modulation of ECG, | ( | |
|
|
| 50-200 μg/ml | ↑Viability, | ( | |
|
| ISO-induced cardiotoxicity in H9c2 murine cardiocytes | 5-20 μM | ↑Viability, phosphorylation of PI3K, Akt, & mTOR, | ( | |
|
| ISO-induced cardiotoxicity in rat | 300 mg/kg/day, p.o., 5, 10 days | ↓LPO, Ca2+ & Mg2+-ATPase activity, | ( | |
| Immunomodulatory activity |
| Randomized, double-blind, placebo-controlled trial in healthy individuals | 2.6 g/day, p.o., 90 days | ↑Proliferation of γδ-T cells & NK cells, | ( |
|
|
| – | ↑Ca2+ flux (EC50 = 9-22 μM), | ( | |
|
|
| 5-200 μg/ml | ↑Proliferation, phagocytosis, secretion of NO, IL-6, IL-10, TNF-α, IFNγ, | ( | |
|
|
| 0.3-10 μM | ↓IFNβ mRNA expression, NF-κB activation, NO production | ( | |
|
|
| 12.5- 50 μM | ↓iNOS, NO, IL-6, IL-1β, ERK & NF-κB-p65 phosphorylation | ( | |
|
| EtOH-induced immunotoxicity in mouse | 300 mg/kg/day, p.o., 28 days | ↑Circulating leukocytes, splenic plaque forming cells, hemagglutination titers to SRBC, secondary IgG response to bovine serum albumin, phagocytes activity, NK cells, IFNγ, delayed-type hypersensitivity | ( | |
|
| Innate immune response in growing piglets | 4% as dietary supplement, p.o., 21 days | ↓Apolipoprotein C-II complement component C6, CRP, CD14 antigen, C4b binding protein α & β chains, fibrinogen | ( | |
|
| Non-stimulated & phytohemagglutinin-stimulated lymphocytes | 50-500 μg/ml | Stimulated cells: ↓IFNγ, IL-10, | ( | |
|
| Randomized double‐blind placebo‐controlled in healthy men | 100 mg, p.o., 6 weeks | Week 3: ↑IgG, monocyte percentage, | ( | |
|
|
|
| ↑HO-1, nuclear translocation of Nrf2, | ( | |
|
|
| 10-1000 μg/ml | Restoration of IL-2 & IFNγ production | ( | |
|
|
| 250 μg/ml | Restoration of phagocytosis & IFNγ production, | ( | |
|
|
| 5 & 10 mg/kg, i.p., single dose | ↓iNOS, NO, COX-2, PG-E2, TNF-α, IL-6, p-STAT1, p-p38 | ( | |
|
| Cyclophosphamide-induced immunosuppression in mouse under SRBC challenge | 100-400 mg/kg/day, p.o., 7 days | ↑WBC, | ( | |
|
|
| 5-100 μg/well | ↓IL-1β by the extract, | ( | |
|
| Burn wound induced in cyclophosphamide-immunosuppressed rat | 0.5 & 1 g/kg/day, p.o., 28 days | ↓Neutropenia & lymphopenia, | ( | |
|
| Aflatoxin-induced immunotoxicity in mouse | 50, 100 mg/kg/day, p.o., 3 weeks | ↓Weight loss, | ( | |
|
| Immunomodulatory effect in healthy mouse | 50-200 mg/kg/day, p.o., 7 days | ↑Spleen & thymus indices, hemagglutination titers to SRBC, delayed-type hypersensitivity, phagocytes activity | ( | |
| Lung protective activity |
| Lambda-cyhalothrin-induced pulmonary damage in rat | 100 mg/kg/day, i.p., 21 days | ↓Cough, nasal discharge, alveolitis, lung inflammation & hyperplasia | ( |
|
| Bleomycin-induced pulmonary toxicity in mouse | 5, 10 mg/kg, i.p., single dose | ↓Pulmonary fibrosis | ( | |
|
| LPS-induced lung inflammation in mouse | 10-60 mg/kg, p.o., single dose | ↓Lung edema, MPO, TNF-α, IL-1β, IL-6, iNOS, COX-2, NF-κB, LPO, | ( | |
|
| OVA-induced airway inflammation in mouse | 25, 50 mg/kg/day, i.p., 5 days | ↓Leukocyte infiltration in BALF, airway hyperresponsiveness, goblet cells hyperplasia, | ( | |
|
| LPS-induced airway inflammation in mouse | 1.5, 15 mg/kg/day, i.p., single dose | ↑HO-1 & oxygenation, | ( | |
|
|
| 10 μM |
| ( | |
|
|
|
|
| ( | |
|
| Bleomycin-induced pulmonary toxicity in rat | 20 mg/kg/day, p.o., 5 weeks | ↓Pulmonary inflammation, fibrosis, leukocytes infiltration into BALF | ( | |
|
| Randomized, triple-blind, placebo-controlled trial in patients with mild & moderate persistent asthma | 100 mg/day, p.o., 8 weeks | Improvement of spirometry parameters, | ( | |
|
| OVA-induced airway inflammation in guinea pigs | 4-16 μg/ml of drinking water | ↓NO, nitrite, IL-4, tracheal response to methacholine & OVA, | ( | |
|
| OVA-induced airway inflammation in mouse | 10-40 mg/kg/day, p.o., 30 days | ↑Regulatory T cells, IFNγ, Foxp3 protein, | ( | |
|
|
|
|
| ( | |
|
| Randomized, double-blind, placebo-controlled trial in 235 patients with postoperative sore throat & postextubation coughing | 0.5 g/30 ml, as gargle, | ↓Sore throat & incidence of coughing | ( | |
|
|
|
| ↑viability, LC3-II/I and Beclin-1, autophagy | ( | |
|
|
| 500 μg/ml of the extract, 2, 20, 200 μM pyrogallol | ↓IL-6, IL-8, GRO-α, GRO-γ, & ICAM-1, | ( | |
|
|
|
|
| ( | |
|
| Randomized, controlled trial in patients with acute respiratory distress syndrome treated with the extract+ conventional drugs or only conventional drugs | 10 g/30 ml, TDS, p.o., 7 days | ↑Oxygenation, | ( | |
|
|
|
|
| ( | |
|
| RSV-induced pulmonary damage in mouse | 30-120 mg/kg/day, p.o., 5 days | Improvement of lung index, | ( | |
|
|
| 0.25-1% | Relaxation in KCl & methacholine-induced tracheal contraction, | ( | |
|
|
| 200 mg/kg, two doses, i.p. | ↓MPO in neutrophils, | ( | |
|
| LPS-induced lung inflammation in mouse | 160 mg/kg, i.p. | Improvement of lung function, | ( | |
|
| Randomized controlled trial in patients with mild asthma | 10 ml, BD, 4 weeks | Improvement of spirometry parameters & quality of life, | ( | |
|
| Bleomycin-induced pulmonary toxicity in rat | 5-40 mg/kg/day, p.o., 28 days | Improvement of lung function & hematological parameters, | ( | |
|
| Bleomycin-induced pulmonary toxicity in mouse | 50, 100 mg/kg/day, p.o., 21 days | ↓Leukocytes infiltration in BALF, hydroxyproline, TGF-β1, MMP-9, collagen 1-α1, fibronectin-1, | ( | |
|
|
| 5, 10 μg/ml | ↓IL−1β, IL−6, IL−8 mRNA & protein expression | ( | |
|
|
|
|
| ( | |
|
| Pb-induced pulmonary toxicity in rat | 200 mg/kg/day, p.o., 5 weeks | ↑AMPK/Nrf2/p62 signaling activation, | ( | |
|
| Carrageenan-induced pulmonary inflammation in mouse | 25-100 mg/kg, p.o., single dose | ↓IL-17A & GITR expressing cells, | ( | |
| Nephroprotective activity |
| As-induced nephrotoxicity in rat | 80 mg/kg/day, p.o., 28 days | ↓BUN, Cr, | ( |
|
|
|
|
| ( | |
|
| High-fructose diet-induced nephrotoxicity in rat | 50-200 μg/kg/day, p.o., 60 days | ↓LPO, Micro-albuminuria & tubular glomerular damage, | ( | |
|
|
|
|
| ( | |
|
| STZ-induced diabetic nephropathy in rat | 125 mg/kg/day, i.p., 21 days | ↓serum uric acid & Cr, microalbuminuria, & renal morphological damage | ( | |
|
| EtOH-induced nephrotoxicity in rat | 40-160 mg/kg/day, p.o., 4 weeks | ↓Renal LPO, TNF-α, IL-6, Casp-3, Casp-8, Casp-9, Bax/Bcl2, | ( | |
|
| Tartrazine-induced nephrotoxicity in rat | 50 mg/kg/day, p.o., 21 days | ↓BUN, Cr, renal LPO, | ( | |
|
| STZ-induced diabetic nephropathy in rat | 20 mg/kg/day, p.o., 21 days | ↓Tubular necrosis, inflammation, & desquamation, | ( | |
|
|
|
|
| ( | |
|
| Cisplatin-induced nephrotoxicity is rat | 150-600 mg/kg/day, p.o., 10 days | ↑Renal CAT, GSH, SOD, | ( | |
|
| Adenine-induced chronic kidney disease in rat | 200-800 mg/kg/day, p.o., 6 weeks | ↓Renal α-SMA, collagen-I & collagen-III, | ( | |
|
|
|
|
| ( | |
|
| Infectious pyelonephritis in rat | 500 mg/kg/day, p.o., 28 days | ↓Leukocyte count, | ( | |
|
| STZ-induced diabetic nephropathy in rat | 10% of the diet weight, 6 weeks | ↓Renal Glut-1 & -2, ACE, iNOS, & NO, | ( | |
|
|
| 2.5, 10 μg/ml | ↓Apoptosis & mitochondrial dysfunction, | ( | |
|
| STZ-induced diabetic nephropathy in rat | 250 mg/kg/day, p.o., 16 weeks | No significant change in BUN & Cr, | ( | |
|
| As-induced nephrotoxicity in mouse | 400 mg/kg/day, p.o., 5 weeks | ↓NF-κB activation, IL−1β, IL−6, CRP, TNF-α, | ( | |
|
| Diatrizoate-induced nephrotoxicity in rat | 100 mg/kg/day, p.o., 8 days | ↓BUN, Cr, Casp-1 & -3, calpain-1, iNOS, eNOS, | ( |
SOD, superoxide dismutase; CAT, catalase; Gpx, glutathione peroxidase; GSH, glutathione; GR, glutathione reductase; GST, glutathione-S-transferase; LPO, lipid peroxidation; p.o., oral; I/R, ischemia-reperfusion; HIV, human immunodeficiency virus; RT, reverse transcriptase; IC50, inhibitory concentration 50%; SI, selective index=cytotoxic concentration 50%/virus inhibitory concentration 50%; CPE, cytopathic effect; GRO, growth-regulated oncogene; IL, interleukin; ICAM, intercellular adhesion molecule; CK-MB: ISO, isoproterenol; STZ, streptozotocin; Cr, creatinine; BUN, blood urea nitrogen; IFN, interferon; TAC, total antioxidant capacity; NO, nitric oxide; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; LPS, lipopolysaccharide; MPO, myeloperoxidase; MMP, matrix metalloproteinase; PG, prostaglandin; COX, cyclooxygenase; STAT, signal transducer and activator of transcription; NF-kB, nuclear factor-κB; WBC, white blood cells; LDH, lactate dehydrogenase; CPK, creatinine phosphokinase; AST, aspartate transaminase; ALT, alanine transaminase; G6PD, glucose 6 phosphate dehydrogenase; LDL, low-density lipoprotein cholesterol; TAG, triacylglycerol; ACE, angiotensin converting enzyme; NPSH, Non protein thiol; RAS, renin angiotensin system; PUFA, poly unsaturated fatty acids; SFA, saturated fatty acid; Ig, immunoglobulin; Casp, caspase; SRBC, sheep red blood cells; DOX, doxorubicin; DNP, dinitrophenyl; HO, heme oxygenase; MCP-1, monocyte chemoattractant protein; VCAM, vascular cell adhesion molecule; RSV, respiratory syncytial virus; BALF, bronchoalveolar lavage fluids; TLR, Toll-like receptor; NQO1, NAD(P)H:quinone oxidoreductase 1; PI3K, phosphatidylinositol-3 kinase; CREB, cAMP response element binding; GSK-3a/b, glycogen synthase kinase 3a/b; ERK, extracellular signal-regulated kinase; As, arsenic; TSH, total sulfhydryl groups; CRP, C-reactive protein; Pb, lead; gGCS, g-glutamylcysteine synthetase; GRP78, glucose−regulated protein 78; PERK, protein kinase RNA−like ER kinase; eIF2a, eukaryotic translation initiation factor−2; JNK, c-Jun N-terminal kinase; AP-1, activator protein-1; CXCL10, interferon-g-inducible protein 10; OVA, ovalbumin; EV, enterovirus; mTOR, mammalian target of rapamycin; RDDP, Reverse Transcriptase-associated DNA Polymerase; RNase H, Ribonuclease H; a-SMA, asmooth muscle actin; STAT, signal transducer and activator of transcription; HSP, heat shock protein; NOX4, NADPH oxidase 4; PPAR, Poly(ADP) ribose polymerase; HMGB, High Mobility Group Box.
Bold studies are antiviral assessments against viral lung pathogens.
Quality assessment of animal studies on the pharmacological activity of traditional Persian medicine-suggested plant possibly beneficial in COVID-19 according to Animal Research: Reporting of In vivo Experiments (ARRIVE) guideline.
| Reference | Validity | Ethical statement | Animals | Experimental procedures | Housing & husbandry | Numbers analyzed | Interpretation & scientific implications | Generalizability/translation |
|---|---|---|---|---|---|---|---|---|
| ( | – | + | + | + | + | + | – | – |
| ( | – | + | + | + | – | + | – | – |
| ( | + | + | + | + | – | – | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | + | – | + | |
| ( | – | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | – | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | – | + | + | + | – | + |
| ( | + | + | + | + | – | – | – | – |
| ( | – | – | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | – |
| ( | + | – | + | + | + | + | – | – |
| ( | + | + | + | + | – | – | – | – |
| ( | + | + | + | + | – | – | – | + |
| ( | + | + | + | + | + | + | – | – |
| ( | – | + | + | + | + | – | – | + |
| ( | + | + | + | + | + | – | – | – |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | – | + | – | + | – | + | – | + |
| ( | – | + | + | + | + | + | – | – |
| ( | – | + | + | + | + | + | – | + |
| ( | – | + | + | + | + | + | – | + |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | – | + | – | + |
| ( | – | + | + | + | – | + | – | + |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | – | + | + | + | + | – | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | – | + | + | + | – | + | – | – |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | – | – | + | – | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | – | – | – |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | – | – | – |
| ( | + | + | + | + | + | + | – | – |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | – | + | – | – |
| ( | – | + | + | + | + | – | – | + |
| ( | – | – | + | + | + | – | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | – | + | – | + |
| ( | + | + | + | + | + | + | – | + |
| ( | + | + | + | + | + | – | – | + |
Figure 1Mechanisms of medicinal plants introduced based on traditional Persian medicine for the management of SARS-CoV-2 infection.